ST世茂(600823.SH):控股股東及其一致行動人累計增持1320萬股 增持價格上限變更為1.8元/股
格隆匯8月3日丨ST世茂(600823.SH)公佈,2023年8月3日,此次增持計劃期間已過半,控股股東峯盈國際及其一致行動人上海伯拉通過上海證券交易所競價交易系統增持公司股份13,200,000股,佔公司總股本的0.35%,增持金額為1,569.70萬元。
近期公司股價持續高於原增持計劃上限1.30元/股,為了能夠切實推進增持計劃,基於對公司長期價值的認可,上述增持主體自願將原定增持價格上限變更為人民幣1.80元/股,增持期間延長9個月,即延期至2024年5月30日,總體增持期限不超過12個月。本次增持計劃的其他內容不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.